Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 8.58 Million USD | 28.85% |
| 2021 | 6.66 Million USD | 5.46% |
| 2020 | 6.31 Million USD | 18.54% |
| 2019 | 5.33 Million USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 1.9 Million USD | 177.88% |
| 2016 | 685.99 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 1.62 Million USD | 11.93% |
| 2012 | 1.45 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 317 Thousand USD | -93.82% |
| 2008 | 5.12 Million USD | -52.18% |
| 2007 | 10.72 Million USD | -8.2% |
| 2006 | 11.68 Million USD | 108.59% |
| 2005 | 5.6 Million USD | -51.73% |
| 2004 | 11.6 Million USD | 32.8% |
| 2003 | 8.73 Million USD | 14.4% |
| 2002 | 7.63 Million USD | 25356.67% |
| 2001 | 30 Thousand USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | -100.0% |
| 1997 | 30 Thousand USD | 0.0% |
| 1996 | - USD | -100.0% |
| 1995 | 300 Thousand USD | -50.0% |
| 1994 | 600 Thousand USD | -1.64% |
| 1993 | 610 Thousand USD | 0.0% |
| 1992 | 610 Thousand USD | 306.67% |
| 1991 | 150 Thousand USD | 400.0% |
| 1990 | 30 Thousand USD | -95.16% |
| 1989 | 620 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 9.62 Million USD | 12.13% |
| 2023 Q3 | 10.82 Million USD | 2.25% |
| 2023 Q2 | 10.59 Million USD | 10.02% |
| 2022 Q1 | 6.82 Million USD | 2.48% |
| 2022 Q3 | 7.99 Million USD | 8.79% |
| 2022 FY | 8.58 Million USD | 28.85% |
| 2022 Q2 | 7.34 Million USD | 7.59% |
| 2022 Q4 | 8.58 Million USD | 7.42% |
| 2021 Q1 | 6.39 Million USD | 1.19% |
| 2021 Q3 | 6.53 Million USD | 0.69% |
| 2021 Q4 | 6.66 Million USD | 1.9% |
| 2021 FY | 6.66 Million USD | 5.46% |
| 2021 Q2 | 6.49 Million USD | 1.58% |
| 2020 FY | 6.31 Million USD | 18.54% |
| 2020 Q1 | 5.79 Million USD | 8.72% |
| 2020 Q2 | 6.14 Million USD | 6.01% |
| 2020 Q3 | 6.25 Million USD | 1.81% |
| 2020 Q4 | 6.31 Million USD | 1.02% |
| 2019 Q2 | 1.44 Million USD | 570.6% |
| 2019 FY | 5.33 Million USD | 0.0% |
| 2019 Q1 | 215.48 Thousand USD | 0.0% |
| 2019 Q4 | 5.33 Million USD | 0.26% |
| 2019 Q3 | 5.31 Million USD | 267.89% |
| 2018 FY | - USD | -100.0% |
| 2018 Q2 | - USD | -100.0% |
| 2018 Q1 | 2.05 Million USD | 7.59% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2017 Q2 | 1.47 Million USD | 60.5% |
| 2017 Q1 | 917.26 Thousand USD | 33.71% |
| 2017 Q4 | 1.9 Million USD | 27.17% |
| 2017 Q3 | 1.49 Million USD | 1.82% |
| 2017 FY | 1.9 Million USD | 177.88% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | 300 Thousand USD | 0.0% |
| 2016 Q3 | 307 Thousand USD | 2.33% |
| 2016 Q4 | 685.99 Thousand USD | 123.45% |
| 2016 FY | 685.99 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q2 | 3000.00 USD | -40.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q1 | 5000.00 USD | -99.69% |
| 2014 Q3 | - USD | -100.0% |
| 2013 FY | 1.62 Million USD | 11.93% |
| 2013 Q4 | 1.62 Million USD | 0.5% |
| 2013 Q3 | 1.61 Million USD | 6.6% |
| 2013 Q2 | 1.51 Million USD | -17.39% |
| 2013 Q1 | 1.83 Million USD | 26.48% |
| 2012 Q1 | 759 Thousand USD | 0.0% |
| 2012 Q2 | 1.38 Million USD | 82.61% |
| 2012 FY | 1.45 Million USD | 0.0% |
| 2012 Q3 | 1.2 Million USD | -13.35% |
| 2012 Q4 | 1.45 Million USD | 20.73% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | -100.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 317 Thousand USD | -84.19% |
| 2010 Q2 | 2 Million USD | 0.0% |
| 2009 FY | 317 Thousand USD | -93.82% |
| 2009 Q1 | 1.82 Million USD | -64.46% |
| 2009 Q2 | - USD | -100.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | 317 Thousand USD | 0.0% |
| 2008 Q1 | 9.46 Million USD | -11.75% |
| 2008 Q4 | 5.12 Million USD | -22.39% |
| 2008 FY | 5.12 Million USD | -52.18% |
| 2008 Q3 | 6.6 Million USD | -19.52% |
| 2008 Q2 | 8.21 Million USD | -13.24% |
| 2007 Q1 | 11.86 Million USD | 1.56% |
| 2007 Q2 | 12.34 Million USD | 4.07% |
| 2007 Q3 | 11.96 Million USD | -3.13% |
| 2007 Q4 | 10.72 Million USD | -10.34% |
| 2007 FY | 10.72 Million USD | -8.2% |
| 2006 Q1 | 5.82 Million USD | 3.91% |
| 2006 Q4 | 11.68 Million USD | 21.03% |
| 2006 FY | 11.68 Million USD | 108.59% |
| 2006 Q2 | 6.51 Million USD | 11.87% |
| 2006 Q3 | 9.65 Million USD | 48.26% |
| 2005 Q4 | 5.6 Million USD | 15.7% |
| 2005 FY | 5.6 Million USD | -51.73% |
| 2005 Q3 | 4.84 Million USD | 17.9% |
| 2005 Q2 | 4.1 Million USD | 20.38% |
| 2005 Q1 | 3.41 Million USD | -70.6% |
| 2004 FY | 11.6 Million USD | 32.8% |
| 2004 Q4 | 11.6 Million USD | 0.97% |
| 2004 Q3 | 11.49 Million USD | 0.7% |
| 2004 Q2 | 11.41 Million USD | 4.2% |
| 2004 Q1 | 10.95 Million USD | 25.35% |
| 2003 Q1 | 7.22 Million USD | -5.37% |
| 2003 Q2 | 8.51 Million USD | 17.84% |
| 2003 FY | 8.73 Million USD | 14.4% |
| 2003 Q4 | 8.73 Million USD | 4.36% |
| 2003 Q3 | 8.37 Million USD | -1.69% |
| 2002 Q3 | 7.66 Million USD | 4113.74% |
| 2002 Q2 | 182 Thousand USD | 506.67% |
| 2002 Q1 | 30 Thousand USD | 0.0% |
| 2002 FY | 7.63 Million USD | 25356.67% |
| 2002 Q4 | 7.63 Million USD | -0.42% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | 30 Thousand USD | 0.0% |
| 2001 Q4 | 30 Thousand USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 FY | - USD | -100.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | 30 Thousand USD | 0.0% |
| 1996 Q2 | 300 Thousand USD | -25.0% |
| 1996 Q1 | 400 Thousand USD | 0.0% |
| 1996 FY | - USD | -100.0% |
| 1996 Q3 | - USD | -100.0% |
| 1995 Q3 | 400 Thousand USD | 33.33% |
| 1995 FY | 300 Thousand USD | -50.0% |
| 1995 Q1 | 400 Thousand USD | 0.0% |
| 1995 Q2 | 300 Thousand USD | -25.0% |
| 1995 Q4 | 400 Thousand USD | 0.0% |
| 1994 Q4 | 400 Thousand USD | 0.0% |
| 1994 FY | 600 Thousand USD | -1.64% |
| 1994 Q1 | 600 Thousand USD | 0.0% |
| 1994 Q2 | 600 Thousand USD | 0.0% |
| 1994 Q3 | 400 Thousand USD | -33.33% |
| 1993 FY | 610 Thousand USD | 0.0% |
| 1993 Q4 | 600 Thousand USD | 0.0% |
| 1993 Q3 | 600 Thousand USD | 0.0% |
| 1992 FY | 610 Thousand USD | 306.67% |
| 1991 FY | 150 Thousand USD | 400.0% |
| 1990 FY | 30 Thousand USD | -95.16% |
| 1989 FY | 620 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 79.164% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -108.275% |
| SQZ Biotechnologies Company | 27.47 Million USD | 68.749% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 80.207% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 71.159% |
| Mesoblast Limited | 118.7 Million USD | 92.768% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -805.332% |
| Genus plc | 233.1 Million USD | 96.317% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -192.965% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -538.963% |
| Marizyme, Inc. | 18.71 Million USD | 54.134% |
| ContraFect Corporation | 2.88 Million USD | -197.987% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1044.667% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -6236.401% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -493.576% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -269.096% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -51.723% |
| MultiCell Technologies, Inc. | 202.58 USD | -4237731.968% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 85.067% |
| EV Biologics, Inc. | 1.49 Million USD | -474.343% |
| Q BioMed Inc. | 4.1 Million USD | -108.882% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 74.064% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1262.532% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -598.899% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1067.167% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 94.995% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 33.946% |
| Skye Bioscience, Inc. | 4.61 Million USD | -86.013% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -866.71% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -5966.366% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -46.225% |
| IMV Inc. | 28.88 Million USD | 70.278% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -33279.991% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -280.14% |
| GB Sciences, Inc. | 1.75 Million USD | -387.976% |
| Alpha Cognition Inc. | 1.22 Million USD | -603.474% |
| HST Global, Inc. | 98.31 Thousand USD | -8631.781% |
| CSL Limited | 12.18 Billion USD | 99.93% |
| Halberd Corporation | 150 Thousand USD | -5623.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -761.655% |
| Resverlogix Corp. | 6.49 Million USD | -32.26% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1697.906% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -3258.869% |
| argenx SE | 20 Million USD | 57.075% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 81.157% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -216.941% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -83860.88% |
| Genscript Biotech Corporation | 417.73 Million USD | 97.945% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -4179.32% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -258.048% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3644.15% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 87.308% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -183.69% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2286.645% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 57.768% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -5675.156% |
| BioStem Technologies, Inc. | 4.71 Million USD | -82.217% |
| ONE Bio Corp. | 19.71 Million USD | 56.455% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -3331.502% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -3351.673% |
| Agentix Corp. | 50 Thousand USD | -17070.0% |
| LadRx Corporation | 33.6 Thousand USD | -25446.033% |
| Cell Source, Inc. | 9.25 Million USD | 7.231% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1035.276% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1035.276% |
| NovAccess Global Inc. | 2.19 Million USD | -290.249% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -21.38% |
| Itoco Inc. | 228.37 Thousand USD | -3659.135% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -3969.203% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -72.286% |
| Kadimastem Ltd | 891.22 Thousand USD | -863.28% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2036.375% |
| CytoDyn Inc. | 30.07 Million USD | 71.456% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1672.72% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -2339.981% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -9.783% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -6908.163% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2669.355% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -81.299% |
| International Stem Cell Corporation | 4.17 Million USD | -105.481% |
| Bioxytran, Inc. | 1.92 Million USD | -345.974% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -13655.147% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -293.645% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -3.235% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -451.92% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -3103.358% |
| Neutra Corp. | 54.15 Thousand USD | -15752.352% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -369.126% |
| PureTech Health plc | 25.51 Million USD | 66.349% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -601.259% |
| IXICO plc | 472.02 Thousand USD | -1718.767% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 44.616% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 86.212% |
| CSL Limited | 12.18 Billion USD | 99.93% |
| Cellectis S.A. | 92.77 Million USD | 90.747% |